Summary
A long-term follow-up study was carried out in 44 Type II diabetic patients to confirm the lack of effect of gliclazide on body weight as well as its hypoglycaemic efficacy and tolerance. Patients were assessed for up to 51 months. The results showed no overall significant change in body weight, 21 patients gaining weight (mean 3.5±2.6 kg), 20 patients losing weight (mean 3.39±2.6 kg) and 3 patients showing no weight change. Satisfactory hypoglycaemic control was achieved in all but 8 patients who were transferred to insulin. Clinical and biochemical tolerance was good.